340B Diversion: The Patient Behind the Discount

340B diversion occurs when a covered entity resells or transfers a discounted outpatient drug to someone who is not its patient. The manufacturer bears the cost of a discount the recipient was not eligible to receive. For hospital and contract-pharmacy staff, the question reaches across the purchase, the prescription and the patient record. Who bought the drug, who received it, and whose patient was that person?

The law makes the patient relationship decisive, then leaves patient undefined. That gap has changed what federal auditors can enforce.

Who Is an Eligible Patient for 340B?

The person receiving the drug must be a patient of the covered entity that bought it. The Health Resources and Services Administration developed patient-eligibility criteria through guidance because the statute leaves patient undefined.

The agency administers the program for eligible hospitals, clinics and other covered entities. Manufacturers supply discounted outpatient drugs, and the participating entity must connect those drugs to its eligible patients. In its audit findings report, the Government Accountability Office gives a concrete example of a diversion finding: the covered entity did not maintain the patient’s health records.

Covered entities can provide discounted drugs to eligible patients regardless of income or insurance status, the Government Accountability Office explains. When insurance reimbursement exceeds the purchase price, the entity can retain revenue to support its work. The program’s financial benefit begins with the price the entity pays for the drug.

That price has a specific origin. The federal pricing regulation sets the ceiling at the preceding quarter’s average manufacturer price minus the Medicaid unit rebate amount.

The Patient Relationship in the Genesis Decision

The patient-definition dispute involving Genesis Health Care turned on who initiated the care behind the prescription. In its account of the November 2023 decision, the Congressional Research Service describes a court rejecting the agency’s interpretation that the covered entity had to initiate the health care service that led to the prescription. The court still required an ongoing patient relationship.

The ruling applied to Genesis. The Congressional Research Service reported that the underlying patient-definition guidance remained in place. For someone reviewing prescriptions from outside providers, that leaves a concrete question about the patient’s ongoing relationship with the covered entity. We examine that relationship and the interpretation used for the transactions at issue with you.

How a Transaction Becomes a Diversion Question

A diversion inquiry follows the discounted drug to the person who received it. The covered entity’s registration identifies the program participant. Its purchase records identify the buyer. The dispensing record identifies the recipient, and the healthcare record supplies the connection to the entity.

Those records answer different parts of the same question. A pharmacy can show that it filled a prescription while the disputed issue sits in the hospital’s account of the patient relationship. The hospital can hold the medical record while the drug was shipped somewhere else. We build the case around the connection between the discounted purchase and the person who received the drug.

The Medicaid payment introduces a separate question. A duplicate discount arises when the same drug is subject to both the 340B price and a Medicaid rebate. Diversion concerns who received the drug. Duplicate discounts concern the discounts charged to the manufacturer. The same prescription may require examination of both the patient relationship and the rebate treatment.

The Government Accountability Office’s January 2020 review found that HRSA assessed potential duplicate discounts in Medicaid fee-for-service but not Medicaid managed care. That left most Medicaid prescriptions outside that check. The payer information can therefore matter alongside the patient record when we examine what an audit actually covered.

Contract Pharmacies Separate the Buyer From the Dispenser

Under the ship-to, bill-to arrangement described in the Health Resources and Services Administration’s contract-pharmacy guidance, the covered entity purchases the drug and the manufacturer ships it directly to the contract pharmacy. The covered entity owns the drug. The pharmacy dispenses it.

That arrangement puts the purchasing and dispensing sides of the transaction in different businesses. The covered entity’s purchase, the pharmacy’s dispensing record and the patient’s relationship with the entity have to be understood together. An insider who works on only one side may know exactly where the connection breaks down.

The agency’s August 1996 guidance allowed a covered entity to contract with one pharmacy at one site. In March 2010, it removed the single-site limit. It permitted multiple pharmacy arrangements subject to guidance addressing diversion, duplicate discounts and patient eligibility.

Both changes came through guidance notices. The statute itself does not mention contract pharmacies. As the Government Accountability Office later explained, that silence became a practical enforcement problem when the agency reconsidered findings based on its guidance. The operating instructions had grown beyond what the agency could enforce.

What HRSA’s Diversion Audits Found

Patient records and contract pharmacies figured heavily in the historical diversion findings. For fiscal years 2012 through 2019, as finalized by September 2020, the Government Accountability Office reported 546 findings involving diversion to ineligible patients, including failures to maintain patient health records.

Its June 2018 review recorded 249 contract-pharmacy diversion findings within 380 diversion findings overall, covering fiscal years 2012 through part of 2017. The outside dispensing arrangement was a substantial part of the audit work.

Why Some Guidance-Based Findings Stopped

Beginning in fall 2019, the Health Resources and Services Administration limited findings to clear and direct violations of the 340B statute. After a covered entity challenged the agency, it concluded that noncompliance with guidance alone did not give it the authority it needed to require and enforce corrective action.

The change reached patient eligibility. The agency stopped issuing diversion findings based solely on its guidance’s definition of an ineligible individual because the statute supplied no criteria for determining patient eligibility. It also stopped some findings involving contract-pharmacy guidance, where the statute did not address the arrangement.

The Government Accountability Office’s October 2025 testimony described the effect on the earlier audit work. Among 199 fiscal-year 2019 audits finalized as of September 2020, HRSA identified 36 instances that would previously have produced findings but did not under the changed approach. The agency still had the audit information. It had changed the standard for calling it a violation.

For the employee who remembers an exception appearing in an earlier audit discussion and disappearing from the final findings, the explanation matters. We examine what the auditor identified, which requirement supported it and why the agency reached its final position.

Corrective Action Has to Reach the Transaction

The Health Resources and Services Administration requires covered entities with audit findings to take corrective action to continue participating in the program. The substance of that correction matters to the staff who know how the drugs actually move.

The Government Accountability Office’s October 2025 oversight testimony, covering follow-up through February of that year, identified a continuing weakness: HRSA’s process for closing audits did not ensure that entities had fully addressed the noncompliance. Earlier work described its reliance on the entity’s own statement that it had addressed all findings. An audit can reach closure while the correction remains unverified.

For a hospital or pharmacy insider, that makes the difference between the corrective-action account and the later transactions worth examining. What did the entity say it changed? Do the subsequent purchases, dispensing records and patient records show that change? We work through those questions with you, including the internal discussions about the original problem and its proposed correction.

The financial obligation can run back to the manufacturer. The statute makes a covered entity that violates the diversion or duplicate-discount prohibition liable to the manufacturer for the discount. What the entity acknowledged, what it disputed and what it actually corrected can explain where an insider’s knowledge adds to the audit account.

What Evidence Is Needed to Prove Fraud?

The evidence we examine connects the discounted purchase, the recipient, the patient relationship and any government billing. Records of the business’s decisions can show what it knew about the discrepancy.

The useful starting point is the problem you recognize from your work. You may understand the patient records, the contract-pharmacy arrangement, the billing or the audit response. We connect that knowledge to the other parts of the transaction and assess the case with whistleblower lawyers who understand pharmaceutical pricing and government health-program payments.

340B Patient Definition Audit Finding Versus FCA Liability

We assess a 340B patient definition audit finding alongside government billing and the business’s decisions to identify the basis for a False Claims Act case. The patient relationship, what the business told the payer and what it knew about the discrepancy are the connections we examine with you.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know Where the Patient Connection Breaks

If you work with hospital patient records, contract-pharmacy dispensing or audit responses and know why the discount does not match the patient relationship, speak to one of our whistleblower experts about what you see. We work with you to build your strongest 340B whistleblower case, bring in pharmaceutical fraud whistleblower lawyers who understand these transactions, and stay beside you throughout the process.